General thoracic surgery
Nonseminomatous germ cell tumors: Assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis

https://doi.org/10.1016/j.jtcvs.2008.09.032Get rights and content
Under an Elsevier user license
open archive

Objectives

Our objective was to explore the pathologic components of residual masses after primary chemotherapy in patients with metastatic nonseminomatous germ cell tumors.

Methods

A multicenter retrospective study was conducted of 71 patients with thoracic residual masses (39 patients had bilateral lung metastasis) after first-line cisplatin-based chemotherapy for disseminated nonseminomatous germ cell tumors. Among the 71 patients, 52 also had a retroperitoneal lymph node dissection.

Results

Pathologic findings in postchemotherapy residual masses included complete necrosis, teratoma, and viable cancer in 31%, 55%, and 14% of patients, respectively. Discordant pathologic findings were evidenced between retroperitoneal lymph node and thoracic (lung or mediastinal lymph nodes) residual masses in 27% of patients. When a bilateral pulmonary resection was performed, only 2 (5%) of 39 patients had discordant histologic findings between the two lungs. Among patients who had necrosis only in residual masses from their first lung (n = 20), 19 (95%) also had necrosis only in contralateral lesions. A single patient had necrosis only in the first lung and some teratoma in the contralateral lung.

Conclusions

This report shows a high rate (95%) of pathologic concordance between the two lungs. Avoiding contralateral lung surgery could therefore be considered when complete necrosis is found in the first lung after induction chemotherapy for nonseminomatous germ cell tumor.

Abbreviations and Acronyms

CI
confidence interval
GCT
germ cell tumor
IGCCCG
International Germ Cell Consensus Classification
NSGCT
nonseminomatous germ cell tumor
OS
overall survival
PFS
progression-free survival
RPLND
retroperitonal lymph node dissection

CTSNet classification

10

Cited by (0)

Read in part at the Forty-first Annual Meeting of the American Society of Clinical Oncology, Orlando, Fla, May 13–17, 2005.